Review on role of progestogen (dydrogesterone) in the prevention of gestational hypertension

Zainul Rashid Mohd. Razi, Adolf E. Schindler

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Gestational hypertension remains one of the main causes of maternal deaths all over the world. Attempts to reduce/prevent the incidence had failed due to lack of understanding of the disease's aetiology. One of the early roles of natural progesterone in the first trimester of pregnancy is to promote formation of wide-calibre spiral vessels that invade into the myometrial layer of the gravid uterus. Theoretically, this will prevent or reduce the incidence of gestational hypertension in the latter half of the pregnancy. The progestogen, dydrogesterone, has similar molecular structure and properties to natural progesterone. A pilot study was undertaken on primigravidae, who have higher risk of developing gestational hypertension. They were supplemented with dydrogesterone in the first trimester (Study Group) and compared with a similar number of primigravidae (Control Group) without supplementation with the progestogen. The incidence of gestational hypertension was significantly lower in the Study Group as compared to the Control Group (1.7% vs. 12.9%, respectively, p<0.001). The incidence of foetal distress was also significantly lower in the Study Group compared to the Control Group (4.3% vs. 18.1%, respectively, p<0.001). Supplementation of the progestogen, dydrogesterone, in the first trimester to primigravidae has shown great potential in reducing or preventing the incidence of gestational hypertension.

Original languageEnglish
Pages (from-to)73-76
Number of pages4
JournalHormone Molecular Biology and Clinical Investigation
Volume27
Issue number2
DOIs
Publication statusPublished - 1 Aug 2016

Fingerprint

Dydrogesterone
Pregnancy Induced Hypertension
Progestins
First Pregnancy Trimester
Incidence
Control Groups
Progesterone
Fetal Distress
Maternal Death
Molecular Structure
Uterus
Cause of Death
Pregnancy

Keywords

  • dydrogesterone
  • gestational hypertension
  • pre-eclampsia
  • pregnancy-induced hypertension
  • progestogen

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Molecular Biology
  • Endocrinology

Cite this

Review on role of progestogen (dydrogesterone) in the prevention of gestational hypertension. / Mohd. Razi, Zainul Rashid; Schindler, Adolf E.

In: Hormone Molecular Biology and Clinical Investigation, Vol. 27, No. 2, 01.08.2016, p. 73-76.

Research output: Contribution to journalReview article

@article{a97aa2821a764a74a98e3d7efae51c65,
title = "Review on role of progestogen (dydrogesterone) in the prevention of gestational hypertension",
abstract = "Gestational hypertension remains one of the main causes of maternal deaths all over the world. Attempts to reduce/prevent the incidence had failed due to lack of understanding of the disease's aetiology. One of the early roles of natural progesterone in the first trimester of pregnancy is to promote formation of wide-calibre spiral vessels that invade into the myometrial layer of the gravid uterus. Theoretically, this will prevent or reduce the incidence of gestational hypertension in the latter half of the pregnancy. The progestogen, dydrogesterone, has similar molecular structure and properties to natural progesterone. A pilot study was undertaken on primigravidae, who have higher risk of developing gestational hypertension. They were supplemented with dydrogesterone in the first trimester (Study Group) and compared with a similar number of primigravidae (Control Group) without supplementation with the progestogen. The incidence of gestational hypertension was significantly lower in the Study Group as compared to the Control Group (1.7{\%} vs. 12.9{\%}, respectively, p<0.001). The incidence of foetal distress was also significantly lower in the Study Group compared to the Control Group (4.3{\%} vs. 18.1{\%}, respectively, p<0.001). Supplementation of the progestogen, dydrogesterone, in the first trimester to primigravidae has shown great potential in reducing or preventing the incidence of gestational hypertension.",
keywords = "dydrogesterone, gestational hypertension, pre-eclampsia, pregnancy-induced hypertension, progestogen",
author = "{Mohd. Razi}, {Zainul Rashid} and Schindler, {Adolf E.}",
year = "2016",
month = "8",
day = "1",
doi = "10.1515/hmbci-2015-0070",
language = "English",
volume = "27",
pages = "73--76",
journal = "Hormone Molecular Biology and Clinical Investigation",
issn = "1868-1883",
publisher = "Walter de Gruyter GmbH",
number = "2",

}

TY - JOUR

T1 - Review on role of progestogen (dydrogesterone) in the prevention of gestational hypertension

AU - Mohd. Razi, Zainul Rashid

AU - Schindler, Adolf E.

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Gestational hypertension remains one of the main causes of maternal deaths all over the world. Attempts to reduce/prevent the incidence had failed due to lack of understanding of the disease's aetiology. One of the early roles of natural progesterone in the first trimester of pregnancy is to promote formation of wide-calibre spiral vessels that invade into the myometrial layer of the gravid uterus. Theoretically, this will prevent or reduce the incidence of gestational hypertension in the latter half of the pregnancy. The progestogen, dydrogesterone, has similar molecular structure and properties to natural progesterone. A pilot study was undertaken on primigravidae, who have higher risk of developing gestational hypertension. They were supplemented with dydrogesterone in the first trimester (Study Group) and compared with a similar number of primigravidae (Control Group) without supplementation with the progestogen. The incidence of gestational hypertension was significantly lower in the Study Group as compared to the Control Group (1.7% vs. 12.9%, respectively, p<0.001). The incidence of foetal distress was also significantly lower in the Study Group compared to the Control Group (4.3% vs. 18.1%, respectively, p<0.001). Supplementation of the progestogen, dydrogesterone, in the first trimester to primigravidae has shown great potential in reducing or preventing the incidence of gestational hypertension.

AB - Gestational hypertension remains one of the main causes of maternal deaths all over the world. Attempts to reduce/prevent the incidence had failed due to lack of understanding of the disease's aetiology. One of the early roles of natural progesterone in the first trimester of pregnancy is to promote formation of wide-calibre spiral vessels that invade into the myometrial layer of the gravid uterus. Theoretically, this will prevent or reduce the incidence of gestational hypertension in the latter half of the pregnancy. The progestogen, dydrogesterone, has similar molecular structure and properties to natural progesterone. A pilot study was undertaken on primigravidae, who have higher risk of developing gestational hypertension. They were supplemented with dydrogesterone in the first trimester (Study Group) and compared with a similar number of primigravidae (Control Group) without supplementation with the progestogen. The incidence of gestational hypertension was significantly lower in the Study Group as compared to the Control Group (1.7% vs. 12.9%, respectively, p<0.001). The incidence of foetal distress was also significantly lower in the Study Group compared to the Control Group (4.3% vs. 18.1%, respectively, p<0.001). Supplementation of the progestogen, dydrogesterone, in the first trimester to primigravidae has shown great potential in reducing or preventing the incidence of gestational hypertension.

KW - dydrogesterone

KW - gestational hypertension

KW - pre-eclampsia

KW - pregnancy-induced hypertension

KW - progestogen

UR - http://www.scopus.com/inward/record.url?scp=84989180943&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84989180943&partnerID=8YFLogxK

U2 - 10.1515/hmbci-2015-0070

DO - 10.1515/hmbci-2015-0070

M3 - Review article

VL - 27

SP - 73

EP - 76

JO - Hormone Molecular Biology and Clinical Investigation

JF - Hormone Molecular Biology and Clinical Investigation

SN - 1868-1883

IS - 2

ER -